192 related articles for article (PubMed ID: 34838031)
1. The tumor immune microenvironment of primary and metastatic HER2- positive breast cancers utilizing gene expression and spatial proteomic profiling.
Schlam I; Church SE; Hether TD; Chaldekas K; Hudson BM; White AM; Maisonet E; Harris BT; Swain SM
J Transl Med; 2021 Nov; 19(1):480. PubMed ID: 34838031
[TBL] [Abstract][Full Text] [Related]
2. B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer.
Steenbruggen TG; Wolf DM; Campbell MJ; Sanders J; Cornelissen S; Thijssen B; Salgado RA; Yau C; O-Grady N; Basu A; Bhaskaran R; Mittempergher L; Hirst GL; Coppe JP; Kok M; Sonke GS; van 't Veer LJ; Horlings HM
Breast Cancer Res; 2023 Oct; 25(1):117. PubMed ID: 37794508
[TBL] [Abstract][Full Text] [Related]
3. Tumor Immune Microenvironment and Response to Neoadjuvant Chemotherapy in Hormone Receptor/HER2+ Early Stage Breast Cancer.
Vanguri RS; Fenn KM; Kearney MR; Wang Q; Guo H; Marks DK; Chin C; Alcus CF; Thompson JB; Leu CS; Hibshoosh H; Kalinsky KM; Mathews JC; Nadeem S; Hollmann TJ; Connolly EP
Clin Breast Cancer; 2022 Aug; 22(6):538-546. PubMed ID: 35610143
[TBL] [Abstract][Full Text] [Related]
4. A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity.
McMullin RP; Wittner BS; Yang C; Denton-Schneider BR; Hicks D; Singavarapu R; Moulis S; Lee J; Akbari MR; Narod SA; Aldape KD; Steeg PS; Ramaswamy S; Sgroi DC
Breast Cancer Res; 2014 Mar; 16(2):R25. PubMed ID: 24625110
[TBL] [Abstract][Full Text] [Related]
5. Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases.
Priedigkeit N; Hartmaier RJ; Chen Y; Vareslija D; Basudan A; Watters RJ; Thomas R; Leone JP; Lucas PC; Bhargava R; Hamilton RL; Chmielecki J; Puhalla SL; Davidson NE; Oesterreich S; Brufsky AM; Young L; Lee AV
JAMA Oncol; 2017 May; 3(5):666-671. PubMed ID: 27926948
[TBL] [Abstract][Full Text] [Related]
6. The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial.
Barroso-Sousa R; Barry WT; Guo H; Dillon D; Tan YB; Fuhrman K; Osmani W; Getz A; Baltay M; Dang C; Yardley D; Moy B; Marcom PK; Mittendorf EA; Krop IE; Winer EP; Tolaney SM
Ann Oncol; 2019 Apr; 30(4):575-581. PubMed ID: 30753274
[TBL] [Abstract][Full Text] [Related]
7. Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets.
Varešlija D; Priedigkeit N; Fagan A; Purcell S; Cosgrove N; O'Halloran PJ; Ward E; Cocchiglia S; Hartmaier R; Castro CA; Zhu L; Tseng GC; Lucas PC; Puhalla SL; Brufsky AM; Hamilton RL; Mathew A; Leone JP; Basudan A; Hudson L; Dwyer R; Das S; O'Connor DP; Buckley PG; Farrell M; Hill ADK; Oesterreich S; Lee AV; Young LS
J Natl Cancer Inst; 2019 Apr; 111(4):388-398. PubMed ID: 29961873
[TBL] [Abstract][Full Text] [Related]
8. High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype.
Dennison JB; Shahmoradgoli M; Liu W; Ju Z; Meric-Bernstam F; Perou CM; Sahin AA; Welm A; Oesterreich S; Sikora MJ; Brown RE; Mills GB
Clin Cancer Res; 2016 Oct; 22(20):5068-5078. PubMed ID: 27172895
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and functional role of subtype-specific tumor-stroma interaction in breast cancer.
Merlino G; Miodini P; Callari M; D'Aiuto F; Cappelletti V; Daidone MG
Mol Oncol; 2017 Oct; 11(10):1399-1412. PubMed ID: 28672102
[TBL] [Abstract][Full Text] [Related]
10. Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer.
Cejalvo JM; Martínez de Dueñas E; Galván P; García-Recio S; Burgués Gasión O; Paré L; Antolín S; Martinello R; Blancas I; Adamo B; Guerrero-Zotano Á; Muñoz M; Nucíforo P; Vidal M; Pérez RM; Chacón López-Muniz JI; Caballero R; Peg V; Carrasco E; Rojo F; Perou CM; Cortés J; Adamo V; Albanell J; Gomis RR; Lluch A; Prat A
Cancer Res; 2017 May; 77(9):2213-2221. PubMed ID: 28249905
[TBL] [Abstract][Full Text] [Related]
11. Analysis of Tumor Microenvironment Heterogeneity among Breast Cancer Subtypes to Identify Subtype-Specific Signatures.
Li J; Wu J; Han J
Genes (Basel); 2022 Dec; 14(1):. PubMed ID: 36672784
[TBL] [Abstract][Full Text] [Related]
12. Identification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer.
Brodsky AS; Xiong J; Yang D; Schorl C; Fenton MA; Graves TA; Sikov WM; Resnick MB; Wang Y
BMC Cancer; 2016 Apr; 16():274. PubMed ID: 27090210
[TBL] [Abstract][Full Text] [Related]
13. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
[TBL] [Abstract][Full Text] [Related]
14. Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer.
Sonnenblick A; Salmon-Divon M; Salgado R; Dvash E; Pondé N; Zahavi T; Salmon A; Loibl S; Denkert C; Joensuu H; Ameye L; Van den Eynden G; Kellokumpu-Lehtinen PL; Azaria A; Loi S; Michiels S; Richard F; Sotiriou C
Int J Cancer; 2020 Jul; 147(1):266-276. PubMed ID: 31904863
[TBL] [Abstract][Full Text] [Related]
15. Stromal SNAI2 Is Required for ERBB2 Breast Cancer Progression.
Blanco-Gómez A; Hontecillas-Prieto L; Corchado-Cobos R; García-Sancha N; Salvador N; Castellanos-Martín A; Sáez-Freire MDM; Mendiburu-Eliçabe M; Alonso-López D; De Las Rivas J; Lorente M; García-Casas A; Del Carmen S; Abad-Hernández MDM; Cruz-Hernández JJ; Rodríguez-Sánchez CA; Claros-Ampuero J; García-Cenador B; García-Criado J; Orimo A; Gridley T; Pérez-Losada J; Castillo-Lluva S
Cancer Res; 2020 Dec; 80(23):5216-5230. PubMed ID: 33023950
[TBL] [Abstract][Full Text] [Related]
16. Immune cell profiles of metastatic HER2-positive breast cancer patients according to the sites of metastasis.
Honkanen TJ; Luukkainen MEK; Tikkanen A; Karihtala P; Mäkinen M; Väyrynen JP; Koivunen JP
Breast Cancer Res Treat; 2022 Jan; 191(2):443-450. PubMed ID: 34817749
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials.
Fernandez-Martinez A; Pascual T; Singh B; Nuciforo P; Rashid NU; Ballman KV; Campbell JD; Hoadley KA; Spears PA; Pare L; Brasó-Maristany F; Chic N; Krop I; Partridge A; Cortés J; Llombart-Cussac A; Prat A; Perou CM; Carey LA
JAMA Oncol; 2023 Apr; 9(4):490-499. PubMed ID: 36602784
[TBL] [Abstract][Full Text] [Related]
18. A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229).
Chia S; Bedard PL; Hilton J; Amir E; Gelmon K; Goodwin R; Villa D; Cabanero M; Tu D; Tsao M; Seymour L
Oncologist; 2019 Nov; 24(11):1439-1445. PubMed ID: 31420468
[TBL] [Abstract][Full Text] [Related]
19. Comparison of tumor microenvironment in primary and paired metastatic ER+/HER2- breast cancers: results of a pilot study.
Zeppellini A; Galimberti S; Leone BE; Pacifico C; Riva F; Cicchiello F; Capici S; Maggioni C; Sala L; Cazzaniga ME
BMC Cancer; 2021 Mar; 21(1):260. PubMed ID: 33691674
[TBL] [Abstract][Full Text] [Related]
20. Cooperation of neurotrophin receptor TrkB and Her2 in breast cancer cells facilitates brain metastases.
Choy C; Ansari KI; Neman J; Hsu S; Duenas MJ; Li H; Vaidehi N; Jandial R
Breast Cancer Res; 2017 Apr; 19(1):51. PubMed ID: 28446206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
